Showing results (1681-1690 of 1,707) with videos related to
Sort By:
Pageof 171
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2025
Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON StudyJin-Ji Yang, Yu Mu, Zhe-Hai Wang, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.Cancer|March 22, 2024
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional studyMeiting Chen, Lu Li, Qing Xia, et al.Cell|June 4, 2020
Proteomic and Metabolomic Characterization of COVID-19 Patient SeraBo Shen, Xiao Yi, Yaoting Sun, et al.Cancer Biology & Medicine|December 10, 2020
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer AssociationYi Ba, Yuankai Shi, Wenqi Jiang, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.Iscience|July 26, 2024
Pulmonary and renal long COVID at two-year revisitJing Wang, Xiao Liang, Yufen Zheng, et al.Pageof 171